600774.Ss
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.44, suggesting potential challenges in meeting short-term obligations. The price-to-book ratio of 1.38 implies that the market values the company at a premium to its book value, while the negative return on equity of -0.88% and return on assets of -0.41% highlight underperformance in generating returns for shareholders and asset utilization.
Profitability metrics show a significant decline, with a net loss of 14,587,170 CNY and an operating loss of 9,727,810 CNY. Gross profit of 641,291,650 CNY is a positive indicator, but it is insufficient to offset the operating and net losses. The company's return on equity and return on assets are below the industry median, indicating that it is not generating returns at a level typical for its sector.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with market-specific downturns or regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year. The operating cash flow of 192,778,250 CNY provides some liquidity, but the negative free cash flow of -1,941,850 CNY and capital expenditure of -60,497,590 CNY suggest that the company is investing in its operations while facing cash flow constraints. The outlook for the next fiscal year is not provided, but the current financial performance raises concerns about future growth.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The company's debt load, with long-term debt of 1,074,711,820 CNY, is a significant portion of its total liabilities, which could impact its financial flexibility. The low dilution risk is supported by the absence of dilutive securities and the alignment of basic and diluted shares outstanding.
Recent events, as reflected in the financial data, include a net loss and a decline in profitability. The company's last actual EPS was 0.02 CNY, and its last actual revenue was 551,395,000 CNY, both of which are below the revenue of 1,175,401,780 CNY reported in the most recent financial snapshot. These figures suggest a decline in performance, which may be attributed to market conditions, operational inefficiencies, or other factors not disclosed in the available data.
- The company is experiencing a net loss and operating loss, indicating poor profitability.
- The company's liquidity position is medium, with a current ratio of 0.44, suggesting potential challenges in meeting short-term obligations.
- The company's debt-to-equity ratio of 0.65 indicates a moderate reliance on debt financing.
- The company's return on equity and return on assets are below the industry median, indicating underperformance in generating returns for shareholders and asset utilization.
- The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year and a lack of disclosed geographic or segment diversification.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 600774.SS Market data — financials · 2026-05-27
- Hanshang Group Co Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Fang YangPresident, Director
- Zeqing WeiExecutive Vice President